» Articles » PMID: 26321501

18-fluorodeoxy-glucose Positron Emission Computed Tomography As Predictive of Response After Chemoradiation in Oesophageal Cancer Patients

Abstract

Introduction: The purpose of this study was to evaluate if a baseline, an interim or a post-chemoradiation (CTRT) 18-fluorodeoxy-glucose positron emission computed tomography (18F-FDG PET/CT) studies could provide information on pathologic response to CTRT and overall survival (OS).

Materials And Methods: Thirty-one patients with histologically proven adenocarcinoma or squamous cell carcinoma of the oesophagus, fit for trimodality therapy were prospectively enrolled. Most were men (93.5%), and had a stage III cancer (74.2%). Chemotherapy consisted of oxaliplatin/5-fluorouracil (45.2%) and taxane/5-fluorouracil (54.8%). All patients underwent a baseline, an interim (performed 12 ± 2 days after the onset of CTRT) and a post-CTRT 18F-FDG PET/CT study. The 18F-FDG PET/CT variables evaluated were at baseline, interim and post-CTRT studies maximum standardised uptake value (SUV max) and total lesion glycolysis (TLG). Clinical and 18F-FDG PET/CT parameters were correlated with pathologic complete response (pathCR) and OS.

Results: Among the 31 patients studied, 61.3% achieved a clinical complete response (cCR) and 87.1% had surgery. The median OS was 35.1 months (95% confidence interval (CI): 19.9-NA). PathCR rate was 22.2%. There was only a marginal association between cCR and pathCR (p = 0.06). None of the other variables was predictive of pathCR. There was association between OS and baseline TLG (p = 0.03) at the optimal cutoff TLG value of 75.15. Additionally, TLG and ΔTLG post-CTRT were also associated with OS (p = 0.01 and 0.03, respectively).

Conclusion: None of the PET parameters is predictive of pathCR but TLG at baseline and post-CTRT are prognostic of OS.

Citing Articles

Value of Computed Tomography Scan for Detecting Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma.

Zeng Y, Liu Y, Li J, Feng B, Lu J Ann Surg Oncol. 2024; 32(3):1635-1650.

PMID: 39586955 DOI: 10.1245/s10434-024-16568-z.


The prognostic value of pretreatment [F]FDG PET/CT parameters in esophageal cancer: a meta-analysis.

Huang M, Wang W, Wang R, Tian R Eur Radiol. 2024; .

PMID: 39570366 DOI: 10.1007/s00330-024-11207-3.


Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.

Liu Y World J Gastroenterol. 2023; 29(34):5020-5037.

PMID: 37753366 PMC: 10518742. DOI: 10.3748/wjg.v29.i34.5020.


Interim position emission tomography-computed tomography during multimodality treatment of locally advanced esophageal cancer: a scoping review.

Zhu H, Hao S, Tseng I, Shen J, Rivin Del Campo E, Davies A Quant Imaging Med Surg. 2023; 13(9):6280-6295.

PMID: 37711778 PMC: 10498200. DOI: 10.21037/qims-22-1306.


Association of dynamic contrast-enhanced MRI and F-Fluorodeoxyglucose PET/CT parameters with neoadjuvant therapy response and survival in esophagogastric cancer.

Withey S, Owczarczyk K, Grzeda M, Yip C, Deere H, Green M Eur J Surg Oncol. 2023; 49(10):106934.

PMID: 37183047 PMC: 10769883. DOI: 10.1016/j.ejso.2023.05.009.


References
1.
Rohatgi P, Swisher S, Correa A, Wu T, Liao Z, Komaki R . Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005; 104(11):2365-72. DOI: 10.1002/cncr.21439. View

2.
Pohl H, Welch H . The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97(2):142-6. DOI: 10.1093/jnci/dji024. View

3.
van Heijl M, Omloo J, van Berge Henegouwen M, Hoekstra O, Boellaard R, Bossuyt P . Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011; 253(1):56-63. DOI: 10.1097/SLA.0b013e3181f66596. View

4.
Ott K, Weber W, Siewert J . The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006; 19(6):433-42. DOI: 10.1111/j.1442-2050.2006.00617.x. View

5.
Suzuki A, Xiao L, Hayashi Y, Macapinlac H, Welsh J, Lin S . Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011; 117(21):4823-33. PMC: 3144261. DOI: 10.1002/cncr.26122. View